Tin tức & Cập nhật

Chỉ hiển thị Multimedia
Subcutaneous atezolizumab favoured over intravenous infusion

Subcutaneous atezolizumab favoured over intravenous infusion

18 Apr 2024 bởiJairia Dela Cruz

Nonsmall cell lung cancer (NSCLC) patients with high PD-L1 expression appear to show a strong preference for receiving atezolizumab subcutaneously rather than intravenously.

18 Apr 2024